3 Stocks Analysts Think Can Outrun the Market - 3/15

The speculative biotech shot

Company: Jade Biosciences, Inc. (SYM: JBIO)
Autoimmune-drug developer with a packed catalyst calendar and a stock still trading in the mid-teens.

Jade is the highest-risk name on this list.

It is also the one that can move the fastest if the data cooperate.

Shares were trading around $13.80 on March 12. Meanwhile, Zacks put the average analyst target at $24.88, MarketBeat showed a consensus target of $26.00, Wedbush recently reiterated an Outperform rating with a $24 target, and Stifel just lifted its target all the way to $40 while keeping a Buy rating.

That kind of spread gets attention.

Because a stock sitting under $14 with Wall Street clustered in the mid-$20s — and one firm up at $40 — is exactly the kind of setup that starts showing up on “strong buy” screens.

The reason analysts are leaning in is not hard to see. Jade reported last week that JADE101 interim Phase 1 data in healthy volunteers are expected in the second quarter of 2026, with a Phase 2 trial in IgA nephropathy expected to begin mid-2026. The company also expects JADE201 to enter a first-in-human rheumatoid arthritis study in Q2 2026, and it ended 2025 with $336.2 million in cash, cash equivalents, and investments, which management says should fund operations into the first half of 2028.

That's what analysts are really buying.

Not current earnings.

Not current revenue.

Time.

Time to hit multiple readouts.

Time to prove the lead program.

Time to turn a clinical-stage story into something bigger.

That said, this is still biotech.

And biotech can humble you in a hurry.

If the data disappoint, the stock does not care what a price target said last week. That is the trade. But if you want the high-upside name on this list, Jade is the one with the cleanest “catalyst plus analyst support” profile.

The beaten-down compounder

Company: KKR & Co. Inc. (SYM: KKR)
Alternative-asset giant with record 2025 metrics and a stock still trading like the market does not trust the group.

KKR is the opposite of Jade.

This is not a science project.

It is a global investment machine.

The stock is trading around $84.32. Yet analysts are still constructive: Barclays maintained Overweight with a $127 target on March 2, UBS maintained Buy with a $125 target on February 20, and Oppenheimer maintained Outperform with a $187 target on February 6.

That is not a subtle vote of confidence.

Even after target cuts, those firms are still saying the stock is materially undervalued from here.

The operating numbers explain why. KKR’s fourth-quarter release showed assets under management of $744 billion, up 17% year over year, fee-paying AUM of $604 billion, up 18%, and new capital raised of $129 billion in 2025, which the firm called a record annual figure. Fee-related earnings for the year hit $3.71 billion, up from $3.27 billion in 2024.

That is not the profile of a broken business.

It is the profile of a business trapped inside a nervous sector.

And that's where the opportunity starts.

Private-asset managers have been under pressure because investors keep worrying about private credit, fundraising durability, and what happens if capital-markets activity stays uneven. But KKR’s actual numbers are still moving in the right direction. Record capital raised. Record fee-related earnings. Bigger AUM. Bigger fee base. That is why Oppenheimer called recent pessimism around the group a buying opportunity.

This is the “grown-up” strong-buy idea on the list.

Less explosive than a biotech.

Less glamorous than a cyber stock.

But if the market stops pricing the whole group like a problem and starts pricing it like a cash-generating franchise again, KKR has a lot of room to re-rate.

The AI-security leader

Company: Palo Alto Networks, Inc. (SYM: PANW)
Cybersecurity platform leader with accelerating AI security demand and a stock Wall Street still sees as a winner.

Palo Alto is the cleanest business on this list.

It is also the one investors already know best.

That can be a blessing and a curse.

Shares are trading around $167.32. Recent analyst calls remain firmly bullish: Wells Fargo initiated coverage with an Overweight rating and a $200 target, Wedbush reiterated Outperform with a $225 target, and TD Cowen reiterated Buy with a $255 target. Zacks showed the broader average target at $208.19.

That gives you the shape of the bull case right away.

This is not a bargain-bin stock.

It is a category leader that analysts still think can go materially higher.

And the company’s latest results gave them plenty to work with. Palo Alto reported fiscal second-quarter revenue of $2.6 billion, up 15% year over year. Next-Generation Security ARR grew 33% to $6.3 billion, and remaining performance obligations rose 23% to $16.0 billion. Management also guided for full-year fiscal 2026 revenue of $11.28 billion to $11.31 billion.

Those are serious numbers.

Especially in a market where every enterprise tech company is trying to explain how AI helps.

Palo Alto is not trying to explain it.

It is already selling into it.

The company said platformization is accelerating because customers want to modernize and normalize their security stack, while CEO Nikesh Arora also pointed to strong adoption of AI security as a long-term trend. That is the kind of language analysts like because it ties the AI story to real budget lines, not just marketing slides.

There is a catch, of course.

There always is.

Palo Alto’s stock got hit after earnings because the market did not love the near-term margin and earnings outlook, especially with acquisition-related costs in the picture. But that is also why the setup still works. If the business had put up those growth numbers and the stock had ripped to new highs, the easy money might already be gone. Instead, you have a leader still growing fast, still taking share, and still getting buy-equivalent calls from major firms while the stock is not far from where it was before the recent stumble.

That is usually where strong-buy cases get interesting.

So what is the takeaway?

Jade is the speculative moonshot with the catalyst calendar.

KKR is the value-and-quality play with record operating metrics.

Palo Alto is the premium franchise with the most durable growth story.

Three very different roads.

Same idea.

Wall Street still sees upside here — and in markets like this, that is worth paying attention to.